Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Name: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
Published: 2020
License: Public Domain

Allogene Therapeutics · 2020

ClinicalTrials.gov · Datasets · License: Public Domain · 2020

Open Source ↗

cell-therapy lymphoma

relapsed or refractory large b cell lymphoma, relapsed or refractory chronic lymphocytic leukemia, relapsed or refractory small lymphocytic lymphoma, car t, cell therapy, allogeneic cell therapy, cellular immuno-therapy, allocar t, allo-501a, allo-647, lbcl, lymphoma, large b-cell lymphoma, cema-cel

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 883085
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.